Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

20161,904 citationsJournal Articlebronze Open Access

Authors

Stephen L. Hauser · University of California, San Francisco

Amit Bar‐Or · McGill University

Gıancarlo Comı · University of British Columbia

Gavin Giovannoni · Queen Mary University of London

Hans‐Peter Hartung · University of British Columbia

Bernhard Hemmer · Düsseldorf University Hospital

Fred Lublin

Abstract

Among patients with relapsing multiple sclerosis, ocrelizumab was associated with lower rates of disease activity and progression than interferon beta-1a over a period of 96 weeks. Larger and longer studies of the safety of ocrelizumab are required. (Funded by F. Hoffmann-La Roche; OPERA I and II ClinicalTrials.gov numbers, NCT01247324 and NCT01412333 , respectively.).

Topics & Keywords

Multiple Sclerosis Research Studies Peripheral Neuropathies and Disorders Rheumatoid Arthritis Research and Therapies

Publication Details

Published in: New England Journal of Medicine

Volume 376, Issue 3, pp. 221-234

DOI: 10.1056/nejmoa1601277

Field-Weighted Citation Impact: 115.18

Command Palette

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Authors

Abstract

Topics & Keywords

Publication Details